We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
BeiGene Ltd | NASDAQ:BGNE | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.02 | 3.38% | 153.58 | 140.10 | 154.00 | 154.47 | 150.726 | 152.11 | 208,460 | 01:00:00 |
Poster Presentations:
Title: | Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a Phase 2 study |
Abstract Code: | PF469 |
Session Title: | Hodgkin lymphoma – Clinical |
Date: | Friday, June 14 |
Time: | 17:30 – 19:00 (CEST) |
Lead Author: | Yuqin Song, M.D., Ph.D. |
Title: | Major responses in MYD88 wildtype (MYD88WT) Waldenström Macroglobulinemia (WM) patients treated with Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) |
Abstract Code: | PF487 |
Session Title: | Indolent and mantle-cell non-Hodgkin lymphoma – Clinical |
Date: | Friday, June 14 |
Time: | 17:30 – 19:00 (CEST) |
Lead Author: | Meletios A. Dimopoulos, M.D. |
Title: | Updated safety and efficacy data in a Phase 1/2 trial of patients with Waldenström Macroglobulinaemia (WM) treated with the Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) |
Abstract Code: | PF481 |
Session Title: | Indolent and mantle-cell non-Hodgkin lymphoma – Clinical |
Date: | Friday, June 14 |
Time: | 17:30 – 19:00 (CEST) |
Lead Author: | Judith Trotman, MBChB, FRACP, FRCPA |
Title: | Pooled analysis of safety data from monotherapy studies of the Bruton Tyrosine Kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies |
Abstract Code: | PS1159 |
Session Title: | Chronic lymphocytic leukemia and related disorders – Clinical |
Date: | Saturday, June 15 |
Time: | 17:30 – 19:00 (CEST) |
Lead Author: | Constantine S. Tam, M.D. |
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,400 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i
Investor Contact Media ContactCraig West Liza Heapes+1 857-302-5189 +1 857-302-5663ir@beigene.com media@beigene.com
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation
1 Year BeiGene Chart |
1 Month BeiGene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions